Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Stroke study reveals key target for improving treatment and suggests that Gleevec may help

Stroke study reveals key target for improving treatment and suggests that Gleevec may help

June 23, 2008

ANN ARBOR, Mich. - For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.

Now, a new paper published online in Nature Medicine reveals why tPA has these limitations. It also gives tantalizing evidence about how those problems might be overcome, if a stroke victim first takes a drug currently used to treat leukemia.




The researchers, from the University of Michigan and the Ludwig Institute at the Karolinska Institutet in Stockholm, Sweden, emphasize that it's still too early to apply their findings - made in mice - to the treatment of stroke victims everywhere.

But the Karolinska Institutet team will soon begin a clinical trial to test the theory in humans, using the leukemia drug known as imatinib (Gleevec). In mice, that drug greatly reduced bleeding, even if tPA wasn't given until five hours after a stroke began.

The new paper details a series of molecular and cellular experiments conducted by the two teams, which began collaborating after hearing of each other's work.

They report that tPA apparently causes its risk of bleeding, and leakage of fluid within the brain, by accident. The culprit: tPA's tendency to act upon a protein called PDGF-CC, and the PDGF-alpha receptor that it binds to. This interaction causes the usually impervious "blood-brain barrier" to become porous, leading to leakage. Gleevec inhibits the PDGF-alpha receptor, apparently counteracting tPA's effect.

This unwanted effect on the blood-brain barrier appears to be unrelated to tPA's main job, which is to break down clots that have lodged in the brain's blood vessels, cutting off blood supply to the area and starving brain tissue until it begins to die.

Such clots cause 80 percent of the 15 million strokes that occur each year worldwide. Five million people die, and 5 million more are permanently disabled, by strokes each year, according to the World Health Organization.

"Our findings may have immediate clinical relevance, and could be applied to find new treatments that will benefit stroke patients," says senior author Daniel Lawrence, Ph.D., professor of cardiovascular medicine in the U-M Medical School and member of the U-M Cardiovascular Center. "By better understanding how the brain regulates the permeability of the blood-brain barrier, and how tPA acts upon that system, we hope to reduce the risks and increase the time window for stroke treatment."

Ulf Eriksson, Ph.D., the leader of the team at the Ludwig Institute at the Karolinska Institutet, comments, "Our research group identified the growth factor PDGF-CC ten years ago and we are now very excited having unraveled a mechanism in the brain involving this factor, which potentially will be a revolution in the treatment of stroke. Together with our clinical colleagues at the Karolinska University Hospital in Stockholm we are now rapidly continuing to explore this exciting possibility in clinical trials involving stroke patients."

Eriksson and Lawrence collaborated with a number of colleagues - including lead author Enming Joe Su, Ph.D. of U-M and teams at the University of Maryland and Emory University - to perform the study.

Some of the mice in the study lacked the natural tPA that the body makes on its own. Some of the mice underwent a procedure that simulated the effects of a clot-based, or ischemic, stroke.

The researchers first demonstrated in non-stroke mice that tPA and PDGF-CC appeared to act on the same target, but that to cause the blood-brain barrier to leak, they both had to be injected directly into the brain side of the barrier. So, something else must be causing tPA to produce this effect when it is delivered through the bloodstream, which is how it is given during stroke treatment.

That's where the PDGF-alpha receptor comes in. The team looked at the activation of these receptors in the side of the brain where a stroke occurred, compared with the other side, in both normal mice and mice that were deficient in natural tPA. This experiment confirmed that the receptor is crucial to the blood-brain barrier permeability that is caused by tPA activation of PDGF-CC.

Knowing that imatinib is a drug that inhibits the PDGF-alpha receptor, the researchers then tested the drug's effect as a preventive agent.

First, they induced strokes in the mice, then gave some of the mice a dose of imatinib one hour after the stroke began. The mice that received the drug had 33 percent less leakage than those that didn't, and 72 hours later, the mice that received imatinib had 34 percent less damage to the brain than the others.

Finally, the researchers tested the effect of imatinib as a pre-treatment to be given before tPA, to protect against bleeding in the brain. They gave imatinib to mice one hour after the stroke began, and then waited until five hours had elapsed after the start of the stroke before giving tPA.

The level of bleeding in the brain was measured by assessing the amount of hemoglobin in the stroke-affected side of the brain. Mice that had received imatinib before tPA had 50 percent less hemoglobin than those that had not received pretreatment.

This last experiment is especially encouraging for its potential to be translated into clinical practice, says Lawrence. Stroke diagnosis often takes hours, especially if a patient delays getting to the hospital or needs to be transferred to a hospital that offers diagnostic brain scans and tPA treatment.

If the clinical trial in human patients in Sweden bears out the findings seen in mice, perhaps Gleevec could be given immediately upon suspicion of stroke-like symptoms, before diagnostic scans and other tests can be made to determine if a patient could benefit from tPA.

University of Michigan Health System



Related Blood-brain Barrier Current Events and Blood-brain Barrier News Articles Blood-brain Barrier Current Events and Blood-brain Barrier News RSS Blood-brain Barrier Current Events and Blood-brain Barrier News RSS
Inhibiting serotonin in gut could cure osteoporosis
An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

Promising new neuroimaging techniques for early detection of Alzheimer's disease
Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease.

New class of brain-protecting drugs emerging
Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.

Common heart medications may also protect against Parkinson's disease, study finds
UCLA researchers have discovered that a specific type of medication used to treat cardiovascular conditions such as hypertension, angina and abnormal heart rhythms may also decrease the risk of developing Parkinson's disease.

Compounds that help protect nerve cells discovered by Duke team
Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.

Experimental drug shows promise against brain, prostate cancers
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

UR Study Reveals Chemo's Toxicity to Brain, Possible Treatment
Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

Scripps research scientists find new link between insulin and core body temperature
A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature.

Scientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

Hybrid molecules show promise for exploring, treating Alzheimer's
One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the disease's devastating symptoms of memory loss and other mental difficulties.
More Blood-brain Barrier Current Events and Blood-brain Barrier News Articles
Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology

Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology
by William M. Pardridge MD (Editor)

Knowledge of the blood-brain barrier forms an essential component in the understanding of a large proportion of medical disciplines. Nevertheless, ignorance in this field still impedes progress in many areas, including cerebrovascular disease, Alzheimer's disease, cerebral AIDS, brain tumors, and the development of effective new neuropharmaceuticals. This introduction for both researchers and clinicians across the medical sciences is intended to aid both those beginning work directly in this area and those wishing simply to be better informed when interpreting information where the blood-brain barrier may be involved. Recent advances in both methodology and biology are detailed in fifty state-of-the-art chapters written by international authorities.

Blood Brain Barrier

Blood Brain Barrier
by Aube



Bonaparte Crossing the Blood-Brain Barrier

Bonaparte Crossing the Blood-Brain Barrier
Alec K. Redfearn And The Eyesores (Primary Contributor)



The Blood Brain Barrier

The Blood Brain Barrier
by Tomas R. Helio (Editor)

The blood-brain barrier (BBB) is a membranic structure that acts primarily to protect the brain from chemicals in the blood, while still allowing essential metabolic function. It is composed of endothelial cells, which are packed very tightly in brain capillaries. This higher density restricts passage of substances from the bloodstream much more than endothelial cells in capillaries elsewhere in the body. Astrocyte cell projections called astrocytic feet (also known as 'glia limitans') surround the endothelial cells of the BBB, providing biochemical support to those cells. The BBB is distinct from the similar blood-cerebrospinal fluid barrier, a function of the choroidal cells of the choroid plexus, and from the Blood-retinal barrier, which can be considered a part of the whole (the...

Relaxity by Relaxity - 10

Relaxity by Relaxity - 10
by Relaxity

The demands of our jobs, families and internal pressures sometimes feel unbearable.This is a common feeling that is not easy to overcome on your own. Relaxity was formulated with you in mind. Relaxity is a natural, whole food based supplement that is made with a proprietary blend of gamma-aminobutyric acid(GABA, naturally produced) and ancient adaptogenic herbs provided in an easy to swallow capsule. Relaxity's GABA has been proven through double-blind placebo controlled clinical tests on humans to increase Alpha brain waves anddecrease Beta brain waves which creates a non-drowsy sense of relaxation and calmness while maintaining mental focus.* GABA is an inhibitory neurotransmitter that is naturally occurring in the brain of humans.The body does not produce enough GABA to overcome the...

The Blood-Brain Barrier and Its Microenvironment: Basic Physiology to Neurological Disease

The Blood-Brain Barrier and Its Microenvironment: Basic Physiology to Neurological Disease
by Elga de Vries (Editor), Alexandre Prat (Editor)

This reference analyzes the cellular and molecular biology and mechanisms of the blood-brain barrier (BBB) and presents the most recent studies on the role of the BBB in the development and initiation of a wide range of physiological and pathological conditions affecting the central nervous system.

Bonaparte Crossing the Blood - Brain Barrier

Bonaparte Crossing the Blood - Brain Barrier
Alec K. Redfearn And The Eyesores (Primary Contributor)



The Blood-Brain Barrier and Drug Delivery to the CNS

The Blood-Brain Barrier and Drug Delivery to the CNS
by Michael Bradbury (Editor), David Begley (Editor), Jorg Kreuter (Editor)

King's College, London, UK. Addresses how to determine drug permeability across the blood-brain barrier more effectively. Focuses on physiological mechanisms influencing the passage of agents into the brain and covers the latest research, problems and solutions, existing strategies, and prospects for future research. For researchers. Expanded-outline format.

Blood-Brain Barriers: From Ontogeny to Artificial Interfaces(2 volume set)

Blood-Brain Barriers: From Ontogeny to Artificial Interfaces(2 volume set)
by Rolf Dermietzel (Editor), David C. Spray (Editor), Maiken Nedergaard (Editor)

This first handbook to integrate developmental and cellular aspects combines the different structural and functional features involved in the regulation of brain perfusion and neuronal function. It highlights pharmacological and biomedical applications with sections on drug delivery and disease-related states as well as explaining in detail the role of astrocytes, shown to be an essential link between neurons and cerebral blood vessels. In addition the book studies how the structural elements interact in response to the dynamics of neuronal activities, necessitating adaptive mechanism of the interface. A significant part of the book describes new approaches to how the barrier can be surmised for drug delivery and how it can be mimicked by artificial in vitro systems for drug testing....

On the Brain of Cartilaginous Fishes: Cerebralization, Astroglial Architecture and Blood-Brain Barrier Composition

On the Brain of Cartilaginous Fishes: Cerebralization, Astroglial Architecture and Blood-Brain Barrier Composition
by Ph.D., Csilla Ari (Author)

This book discusses the correlation between the cerebralization, the astroglial architecture and the blood-brain barrier composition in cartilaginous fishes. Chondrichthyes display a wide range of cerebralization, with the highest brain weight/body weight ratio represented by galeomorph sharks and batoids of the myliobatiform order. The examination was extended to representatives of all these important groups and the book presents the first study on the glial architecture of a Holocephali as well. The present work supplements the former glial impregnation studies; three different astroglial markers - glial fibrillary acidic protein, S-100 protein, and glutamine synthetase - were investigated by immunohistochemical methods, applying both diaminobenzidine and fluorescent ...

© 2010 BrightSurf.com